Abcuro
Latest round
- Series D
Last raised
- Aug 2026
Total raised
- $255M
Investors
- 21
About Abcuro
Based in the US, Abcuro, Inc. is a biotechnology company focused on developing innovative therapies targeting autoimmune diseases and cancers through the modulation of cytotoxic T cells., founded in 2015 and headquartered in Newton, US, is dedicated to advancing treatments for autoimmune diseases and cancer. In August 2026, Abcuro, Inc. Abcuro, Inc. specializes in developing breakthrough therapies for autoimmune diseases and cancer, focusing on the modulation of cytotoxic T cells. Its lead product candidate, ulviprubart, is an investigational monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting the killer cell lectin-like receptor G1 (KLRG1). This product aims to address critical medical needs in conditions such as inclusion body myositis, T Cell Large Granular Lymphocytic Leukemia, and certain T and NK cell lymphomas, where cytotoxic T cells contribute to chronic tissue damage or malignancy. Abcuro's products are primarily aimed at healthcare providers, hospitals, and specialized clinics in North America and select European markets, focusing on patients suffering from rare diseases and cancers with limited treatment options. Abcuro's revenue model is structured around business-to-business transactions, partnering with healthcare institutions and pharmaceutical companies. Revenue is generated through the development and potential commercialization of ulviprubart, designed for rare diseases and cancers. Collaborations may involve co-development or licensing agreements, generating income through upfront payments, milestones, and royalties on product sales. By collaborating with healthcare providers and specialty pharmacies, Abcuro establishes a distribution network to enhance access to its therapies.In February 2025, Abcuro, Inc.
Who invested in Abcuro
21 investors across 5 rounds
See all investors in Abcuro
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abcuro
Who invested in Abcuro?
Abcuro has 21 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abcuro raised?
Abcuro has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Abcuro last raise money?
Abcuro's most recent round on record is a Series D, in Aug 2026.
What does Abcuro do?
Abcuro is a biotechnology company.
Where is Abcuro headquartered?
Abcuro is headquartered in Newton, US.
Which VCs invest in companies like Abcuro?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Abcuro's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Abcuro? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.